Home
HelpTest ID RASFP RAS/RAF Targeted Gene Panel, Next-Generation Sequencing, Tumor
Useful For
Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
Identifying mutations that may help determine prognosis for patients with solid tumors
Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
Genetics Test Information
This extended RAS/RAF panel test uses targeted next-generation sequencing to evaluate for somatic mutations within the BRAF (exons 11 and 15), HRAS (exons 2 and 3), NRAS (exons 2, 3, 4), and KRAS (exons 2, 3, 4) genes. This includes, but is not limited to, the testing of somatic mutations in KRAS codons 12, 13, 59, 61, 117, 146; NRAS codons 12, 13, 59, 61,146; HRAS codons 12, 13, 61; and BRAF codons 594, 596, 600. See Targeted Gene Regions Interrogated by RAS/RAF Gene Panel in Special Instructions for details regarding the targeted gene regions identified by this test.
Of note, this test is performed to evaluate for somatic mutations within tumor samples. This test does not assess for germline alterations within the genes listed.
Highlights
This test provides evaluation of BRAF (including V600), HRAS, NRAS (includes codons 12, 13, 59, 61, and 146), and KRAS (includes codons 12, 13, 59, 61, 117, and 146) genes for somatic mutations.
Additional Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SLIRV | Slide Review in MG | No | Yes |
Testing Algorithm
When this test is ordered, slide review will always be performed at an additional charge.
Special Instructions
Method Name
Polymerase Chain Reaction (PCR)-Based Next Generation Sequencing
Reporting Name
RAS/RAF Panel, TumorSpecimen Type
VariesAdvisory Information
Necessary Information
Pathology report (final or preliminary) at minimum containing the following information must accompany specimen in order for testing to be performed:
1. Patient name
2. Block number-must be on all blocks, slides and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue
Specimen Required
This assay requires at least 20% tumor nuclei.
-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue144 mm(2)
-Minimum amount of tumor area: tissue 36 mm(2).
-These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.
-Tissue fixation: 10% neutral buffered formalin, not decalcified
-For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing in Special Instructions. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).
Preferred:
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.
Acceptable:
Specimen Type: Tissue slide
Slides: 1 stained and 10 unstained
Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 10 unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.
Specimen Type: Cytology slide (direct smears or ThinPrep)
Slides: 1 to 3 slides
Collection Instructions: Submit 1 to 3 slides stained and cover slipped with a preferred total of 5000 nucleated cells or a minimum of at least 3000 nucleated cells.
Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.
Additional Information: Cytology slides will not be returned.
Specimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Ambient (preferred) | ||
| Frozen | |||
| Refrigerated | |||
Reference Values
An interpretive report will be provided.
Day(s) and Time(s) Performed
Monday through Friday; Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor
81210-BRAF (v-raf murine sarcoma viarl oncogene humolog B1) (eg, colon cancer), gene analysis, V600E variant
81275-KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) (eg, carcinoma) gene analysis, variants in codons 12 and 13
81403-HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2 sequence
81311-NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)
Slide Review
88381-Microdissection, manual
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| RASFP | RAS/RAF Panel, Tumor | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 36725 | Result Summary | 50397-9 |
| 36726 | Result | 82939-0 |
| 36727 | Interpretation | 69047-9 |
| 36728 | Additional Information | 48767-8 |
| 36729 | Specimen | 31208-2 |
| 36730 | Source | 33725-3 |
| 36731 | Tissue ID | 80398-1 |
| 36732 | Released By | 18771-6 |
NY State Approved
YesForms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Oncology Test Request (T729)